Financial Performance - The company's revenue for Q3 2023 was CNY 116,354,484.54, representing a decrease of 21.55% compared to the same period last year[5]. - Net profit attributable to shareholders was CNY 27,192,127.78, down 44.59% year-on-year[5]. - The basic earnings per share decreased to CNY 0.07, a decline of 41.67% compared to the previous year[6]. - The net profit attributable to shareholders decreased by 44.59% in the current reporting period due to the ongoing low performance of the pig breeding industry[11]. - The total revenue for the first three quarters decreased by 16.46% year-on-year, with a revenue drop of 21.55% in the third quarter[11]. - Net profit for the third quarter of 2023 was CNY 36,484,405.67, a decline of 49.6% from CNY 72,349,115.33 in the same quarter of 2022[22]. - The total comprehensive income attributable to the parent company for Q3 2023 was CNY 37,124,297.77, a decrease from CNY 72,362,110.69 in Q3 2022, reflecting a decline of approximately 48.7%[23]. - Basic and diluted earnings per share for Q3 2023 were both CNY 0.09, down from CNY 0.18 in Q3 2022, indicating a 50% decrease[23]. Research and Development - Research and development expenses amounted to CNY 13,927,155.79, a decrease of 41.47% year-on-year, accounting for 11.97% of revenue[6]. - Research and development expenses decreased by 41.47% in the current reporting period due to a reduction in capitalized R&D expenditures[11]. - Research and development expenses for the first three quarters of 2023 amounted to CNY 30,259,274.15, an increase of 14.1% compared to CNY 26,393,024.56 in 2022[21]. Cash Flow and Liquidity - The company reported a cash flow from operating activities of CNY -54,675,362.33 for the year-to-date[5]. - Cash inflow from operating activities for the first three quarters of 2023 was CNY 141,632,602.99, compared to CNY 147,079,311.43 in the same period of 2022, representing a decline of about 3.0%[26]. - The net cash flow from operating activities for the first three quarters of 2023 was -CNY 54,675,362.33, worsening from -CNY 41,221,111.53 in the previous year[26]. - The ending cash and cash equivalents balance for Q3 2023 was CNY 38,876,146.49, an increase from CNY 25,280,141.36 at the end of Q3 2022[27]. - The company's cash and cash equivalents decreased from 52,742,562.11 RMB at the end of 2022 to 39,005,070.45 RMB as of September 30, 2023[17]. - The company's cash and cash equivalents were CNY 631,999,472.35, down from CNY 705,503,694.52 in the previous year, indicating a decrease of 10.4%[20]. - The company reported a cash outflow of CNY 64,232,476.75 for employee compensation in the first three quarters of 2023, up from CNY 56,883,254.65 in the same period of 2022, indicating an increase of about 12.4%[26]. Assets and Liabilities - Total assets at the end of the reporting period were CNY 1,611,375,470.59, reflecting a slight increase of 0.39% from the beginning of the year[6]. - The company's total assets as of the end of the third quarter of 2023 were CNY 1,611,375,470.59, slightly up from CNY 1,605,150,595.38 at the end of 2022[20]. - Total liabilities decreased to CNY 89,552,103.93 in the third quarter of 2023 from CNY 108,279,555.46 in the same quarter of 2022, a reduction of 17.3%[19]. - The company's total equity attributable to shareholders was CNY 1,502,459,258.76, an increase from CNY 1,496,871,039.92 in the previous year, representing a growth of 0.4%[20]. Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 10,649[13]. - The largest shareholder, Yang Yufang, holds 21.93% of the shares, while the second-largest shareholder, UNITED BIOMEDICAL, INC., holds 10.52%[14]. Other Information - Non-operating income included government subsidies totaling CNY 268,958.78 for the current period[10]. - The company experienced a loss of CNY 341,413.60 from the disposal of non-current assets in the current period[10]. - The company is experiencing a decline in government procurement sales of foot-and-mouth disease vaccines, impacting overall revenue[11]. - The company has not disclosed any significant new strategies or market expansions in the current report[16].

证券代码：688098 证券简称：申联生物 公告编号：2023-033 申联生物医药（上海）股份有限公司 关于使用部分闲置募集资金及闲置自有资金进行现 金管理的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 申联生物医药（上海）股份有限公司（以下简称"公司"）于 2023 年 10 月 30 日召开了第三届董事会第十一次会议及第三届监事会第八次会议，审议通过 了《关于使用部分闲置募集资金进行现金管理的议案》和《关于使用闲置自有资 金进行现金管理的议案》，同意公司在确保不影响募集资金项目建设和募集资金 使用计划及不影响公司正常经营的前提下，使用额度不超过人民币 5,000 万元 （包含本数）的闲置募集资金进行现金管理，用于购买流动性好、安全性高的保 本型金融产品，同意公司使用额度不超过 3 亿元（包含本数）的自有资金，用于 购买流动性好、安全性高的金融产品。在上述额度范围内，公司根据募集资金使 用情况及公司经营情况，将闲置募集资金及闲置自有资金分笔按不同期限投资上 述现金管理产品，使用期限自董事会审议通过之日起 12 ...

表决结果：3 票同意，0 票反对，0 票弃权。 申联生物医药（上海）股份有限公司 第三届监事会第八次会议决议公告 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、监事会会议召开情况 申联生物医药（上海）股份有限公司（以下简称"公司"）第三届监事会第 八次会议于 2023 年 10 月 30 日以现场结合通讯方式召开，本次会议通知已于 2023 年 10 月 25 日以邮件方式送达公司全体监事。本次会议由监事会主席叶尔 阳先生主持，会议应出席监事 3 名，实际出席监事 3 名，会议的召集和召开程序 符合《中华人民共和国公司法》和《公司章程》等相关规定，会议形成的决议合 法、有效。 二、监事会会议审议情况 （一）审议通过《关于审核公司<2023 年第三季度报告>的议案》 监事会审核了公司《2023 年第三季度报告》，了解并监督了三季度报告的编 制及审议程序，全体监事列席董事会并了解董事会对三季度报告的审议情况。监 事会认为《2023 年第三季度报告》的编制、审核以及董事会的审议程序符合法律 法规、公司章程等相关规定，报告内 ...

一、募集资金基本情况 经中国证券监督管理委员会《关于同意申联生物医药（上海）股份有限公司 首次公开发行股票注册的批复》（证监许可[2019]1743 号）核准，并经上海证券 交易所同意，公司发行人民币普通股（A 股）不超过 5,000 万股，发行价格为每 股 8.80 元，募集资金总额 44,000.00 万元，募集资金净额为人民币 40,017.50 万 元。上述资金到位情况已经大华会计师事务所（特殊普通合伙）验证，并由其出 具"大华验字[2019]000402 号"验资报告。 公司对募集资金采取了专户存储制度，设立了相关募集资金专项账户。募集 资金到账后，已全部存放于经公司董事会批准开设的募集资金专项账户内，并与 保荐机构、存放募集资金的银行签署了《募集资金三方监管协议》。 2022 年 4 月 28 日，公司披露了《申联生物医药（上海）股份有限公司关于 首次公开发行股票募投项目结项并将节余募集资金用于实施动物灭活疫苗项目 及永久补充流动资金的公告》，拟将首次公开发行募集资金投资项目"悬浮培养 口蹄疫灭活疫苗项目"结项，并将节余募集资金 9,903 万元用于实施动物灭活疫 苗项目，结余募集资金剩余部分永久 ...

证券代码：688098 证券简称：申联生物 公告编号：2023-032 申联生物医药（上海）股份有限公司 自愿披露关于签署《抗非洲猪瘟的蓝耳病基因工程活载体 疫苗技术开发（合作）合同》的公告 公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 事项概述：申联生物医药（上海）股份有限公司（以下简称"公司"） 近日与中国农业科学院上海兽医研究所（以下简称"上兽研"）签署了《抗非 洲猪瘟的蓝耳病基因工程活载体疫苗技术开发（合作）合同》，双方拟共同开 发抗非洲猪瘟的蓝耳病基因工程活载体疫苗，该疫苗能同时预防非洲猪瘟和猪 蓝耳病。 重要风险提示：疫苗产品具有研发周期长、技术难度大、研发风险高等 特点，同时受到外部环境以及行政审批等因素的影响，存在研发失败及不能商 业化生产、销售的风险。请投资者谨慎决策、注意投资风险。 公司近日与上兽研签署了《抗非洲猪瘟的蓝耳病基因工程活载体疫苗技术开 发（合作）合同》，双方拟共同研究开发抗非洲猪瘟的蓝耳病基因工程活载体疫 苗。根据《上海证券交易所科创板股票上市规则》《公司章程》等相关规定，本 ...

Financial Performance - The company's operating revenue for the first half of 2023 was approximately ¥123.07 million, a decrease of 10.99% compared to the same period last year[17]. - The net profit attributable to shareholders for the first half of 2023 was approximately ¥9.93 million, down 57.35% year-on-year[17]. - The net cash flow from operating activities was negative at approximately -¥43.83 million, indicating a decline in operational efficiency[17]. - Basic earnings per share for the first half of 2023 were ¥0.02, a decrease of 66.67% compared to the same period last year[18]. - The company's total assets as of the end of the reporting period were approximately ¥1.55 billion, a decrease of 3.27% from the end of the previous year[17]. - The company's operating revenue decreased by 15.19 million yuan, representing a decline of 6% year-on-year due to reduced government procurement sales of foot-and-mouth disease vaccines[19]. - Gross profit decreased by 15.34 million yuan, with the total profit decline closely matching the gross profit decrease[20]. Research and Development - Research and development expenses accounted for 33.31% of operating revenue, an increase of 15.18 percentage points compared to the same period last year[18]. - The total R&D investment reached ¥40,991,454.92, a significant increase of 63.52% compared to ¥25,068,739.52 in the previous year, with the proportion of R&D investment to operating income rising to 33.31% from 18.13%[63]. - The company is actively developing mRNA vaccines and drugs, with a production facility under construction for this purpose[46]. - The company has established multiple technology platforms, including inactivated vaccines and synthetic peptide vaccines, and is progressively building an mRNA technology platform to enhance its core competitiveness[54]. - The company has achieved significant advancements in its inactivated vaccine technology platform, including five key core technologies that improve vaccine safety and effectiveness[55]. Market Position and Strategy - The company is a high-tech enterprise specializing in the R&D, production, and sales of veterinary biological products, with a focus on vaccines for major animal diseases[24]. - The company is actively pursuing market-oriented sales, which are still in a growth phase but have not yet reached maturity[19]. - The company has established a stable supply chain with suppliers, ensuring timely and quality delivery of raw materials[33]. - The sales strategy includes both government procurement and market-based sales, with a focus on large-scale farming clients and strategic partnerships[35]. - The company is expanding its product offerings to include pet biological products, reflecting a strategy to diversify into new markets[48]. Regulatory and Compliance - The report indicates that the financial statements have not been audited, which may affect investor confidence[6]. - The regulatory environment is becoming stricter, with new drug registration processes expected to take 7-8 years or longer, increasing the investment required for R&D[46]. - The company is adhering to national policies aimed at enhancing the quality and safety of veterinary drugs, which may impact operational strategies[45]. - The company is committed to maintaining compliance with evolving regulations, which is critical for sustaining its market position[46]. Environmental Responsibility - In the first half of 2023, the company invested 1,145,300 CNY in environmental protection[137]. - The total wastewater discharge in the first half of 2023 was 2,600.1 tons, with chemical oxygen demand at 2.3021 tons, well below the limit of 500 mg/l[138]. - The company has established a sound environmental protection mechanism and effectively managed waste emissions[137]. - The company has installed online monitoring facilities for various pollutants, ensuring real-time monitoring of emissions and compliance with environmental standards[148]. Corporate Governance - The company has committed to improving its governance structure to protect the rights of shareholders, especially minority shareholders[167]. - The company will ensure compliance with legal and regulatory requirements in its operations and governance practices[167]. - The company has established a fundraising management system to ensure that raised funds are used legally and appropriately, with a focus on expanding the variety and production scale of foot-and-mouth disease vaccines[166]. - The company has pledged to take legal responsibility for any violations of its commitments regarding competition and related-party transactions[165]. Product Development and Innovation - The company has successfully developed a range of vaccines and diagnostic products, showcasing its capabilities in innovation and product development[47]. - The company has received product approval for several diagnostic kits, including those for African swine fever and foot-and-mouth disease, expanding its diagnostic product pipeline[61]. - The company is focusing on enhancing its independent control capabilities in the synthetic peptide supply chain by promoting domestic resource utilization[58]. - The company has achieved product approval for the bivalent inactivated vaccine for foot-and-mouth disease (FMD) in cattle and sheep, with a total investment of RMB 2.8 billion and RMB 1.21 billion spent in the current period[70]. Financial Management - The company's cash and cash equivalents increased to ¥148,836,724.48, representing 9.59% of total assets, a 182.19% increase compared to the previous year[118]. - The company's trading financial assets decreased to ¥90,445,579.28, accounting for 5.83% of total assets, a decline of 70.36% year-over-year[118]. - The company reported a significant increase in prepayments, which rose by 126.71% to ¥6,204,374.78, representing 0.40% of total assets[118]. - The company has completed the construction of the animal live vaccine workshop, which has a planned area of 6,093.04 square meters and an expected annual production capacity of 70 million doses[123].

证券代码：688098 证券简称：申联生物 公告编号：2023-031 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 申联生物医药（上海）股份有限公司 重要内容提示： 关于参加 2023 年半年度制药及生物制品行业 会议线上交流时间：2023 年 9 月 7 日(星期四)下午 13:00-15:00 集体业绩说明会的公告 本次业绩说明会以网络文字互动形式召开，公司将针对 2023 年半年度的经 营成果及财务指标的具体情况与投资者进行互动交流和沟通，在信息披露允许的 范围内就投资者普遍关注的问题进行回答。 二、说明会召开的时间、地点 （一）会议线上交流时间：2023 年 9 月 7 日下午 13:00-15:00 （二）会议召开方式：网络文字互动 （三）网络文字互动平台：上海证券交易所上证路演中心（网址： http://roadshow.sseinfo.com/） 会议召开方式：网络文字互动 线 上 文 字 互 动 平 台 ： 上 海 证 券 交 易 所 上 证 路 演 中 心 （ 网 址 ： http://roadsho ...

二、监事会会议审议情况 证券代码：688098 证券简称：申联生物 公告编号：2023-030 申联生物医药（上海）股份有限公司 第三届监事会第七次会议决议公告 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、监事会会议召开情况 申联生物医药（上海）股份有限公司（以下简称"公司"）第三届监事会第 七次会议于 2023 年 8 月 29 日以现场结合通讯方式召开，本次会议通知已于 2023 年 8 月 19 日以邮件方式送达公司全体监事。本次会议由监事会主席叶尔阳先生 主持，会议应出席监事 3 名，实际出席监事 3 名，会议的召集和召开程序符合 《中华人民共和国公司法》和《公司章程》等相关规定，会议形成的决议合法、 有效。 （一）审议通过《关于审核<2023 年半年度报告>及其摘要的议案》 监事会审核了公司《2023 年半年度报告》及其摘要，了解并监督了半年度报 告的编制及审议程序，全体监事列席董事会并了解董事会对半年度报告的审议情 况。监事会认为《2023 年半年度报告》的编制、审核以及董事会的审议程序符合 法律法规、 ...

证券代码：688098 证券简称：申联生物 公告编号：2023-029 申联生物医药（上海）股份有限公司 2023 年 1-6 月募集资金存放与使用情况的专项报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 申联生物医药（上海）股份有限公司（以下简称"公司"）董事会根据中国证券 监督管理委员会(以下简称"证监会")《上市公司监管指引第 2 号——上市公司募集 资金管理和使用的监管要求（2022 年修订）》及《上海证券交易所科创板上市公司 自律监管指引第 1 号——规范运作》等相关法律、法规及规范性文件的规定，编制 了 2023 年 1-6 月关于公司首次公开发行 A 股股票募集资金存放与实际使用情况的 专项报告。现将截至 2023 年 6 月 30 日公司募集资金存放与实际使用情况专项说明 如下： 一、募集资金基本情况 （一）实际募集资金金额、资金到账时间 根据证监会作出的《关于同意申联生物医药（上海）股份有限公司首次公开发 行股票注册的批复》（证监许可[2019]1743 号），同意公司向社会公开发行人民币普 通股（ ...

公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 申联生物医药（上海）股份有限公司（以下简称"公司"）近日通过了农业 农村部畜牧兽医局兽药临床试验质量管理规范（GCP）的监督检查。公司本次通 过监督检查并符合兽药临床试验质量管理规范（GCP）要求的试验项目信息如下： 公司本次通过兽药临床试验质量管理规范（GCP）监督检查，短期内对公司 申联生物医药（上海）股份有限公司 自愿披露关于通过农业农村部兽药 GCP 监督检查的 公告 | 分类 | 试验项目 | 动物实验场所名称 | | --- | --- | --- | | 兽药临床试 | 猪安全性试验（兽用生物制 | 永登县剑锋养殖场、三门峡市为民实业有 | | | 品） | 限公司、成都茵莱牧业专业合作社 | | 验质量管理 规范（GCP） | 猪有效性试验（兽用生物制 | 永登县剑锋养殖场、三门峡市为民实业有 | | | | 限公司、成都茵莱牧业专业合作社、申联 | | | 品） | 生物医药（上海）股份有限公司兰州分公 | | | | 司（动物实验室） | 证券代码：6880 ...